The ongoing role of beta blockers in the CVD treatment paradigm

Combination of hypertension and hypercholesterolemia

Podcast & Infographic

The ongoing role of beta blockers in the CVD treatment paradigm

E-learning Modules

Launch: 30 September 2024


Beta blockers are established treatments for many cardiovascular conditions and are indicated for the management of heart failure (HF), coronary artery disease (CAD), cardiac arrhythmias, hypertension, aortic dissection, and portal hypertension (Farzam, 2023). Beta blockers are disease-modifying medications that are mainstay treatments for HF with reduced ejection fraction (HFrEF) (Paolillo, 2021). Consequently, the most recent European guidelines for HFrEF management recommend beta blockers as first-line therapies in patients who are clinically stable and euvolemic (McDonagh, 2021). In patients with acute HF, beta blockers should be initiated in hospital settings after the patient is hemodynamically stabilized (McDonagh, 2021). However, to achieve full prognostic benefits, beta-blocker administration needs to be titrated to the maximum tolerable dose (Paolillo, 2021). Despite guideline recommendations and the potential benefits of these agents, physicians underuse beta blockers for patients with HFrEF who have other comorbidities even when these are not contraindications to beta-blocker use (Paolillo, 2021).  Therefore, the presence of such comorbidities should not limit the use of beta blockers in patients with HFrEF. Beta blockers are also considered first-line treatment to control heart rate and relieve CAD due to their anti-ischemic effects (Knuuti, 2020). Studies also show that early and long-term beta-blocker treatment reduces death and reinfarction rates in patients with CAD (e.g. Kim, 2020) reduces all-cause mortality in CAD and diabetes mellitus (Chen, 2023). Therefore, this podcast highlights to healthcare professionals the need to understand the appropriate position of beta blockers in order to treat patients with CAD who will benefit from their well-established pharmacological effects.

Learning Objectives

After listening to this podcast, participants will be able to:

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure. Some content of interest to gynaecologists, midwives, nurses involved in women’s health care.


English with voice-over into Russian and Chinese


Brian Tomlinson

Brian Tomlinson

Faculty of Medicine · Macau University of Science & Technology ·
Taipa, Macau, China

Click to listen to the podcast

Save the Date

Download Save the Date

· Brian Tomlinson ·

Brian Tomlinson is Professor in the Faculty of Medicine at Macau University of Science & Technology since 2019 and Consultant at the University Hospital in Macau. He was previously Professor of Medicine and Therapeutics in the Department of Medicine and Therapeutics from 2007 until 2015 and Head of the Division of Clinical Pharmacology from 2003 at the Chinese University of Hong Kong. He was Honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong from 1990 to 2019. He trained as a specialist in Internal Medicine and Clinical Pharmacology at the Middlesex Hospital and University College London and he has a particular clinical and research interest in lipid disorders, hypertension, diabetes and cardiovascular disease. He has participated in many early phase clinical trials with various types of medication and in later phase international trials in hyperlipidaemia, hypertension and diabetes. He is an author on over 500 publications in peer-reviewed journals. He is currently the Chair of the Asia-Pacific Federation of the International Atherosclerosis Society and is a Past-President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases.

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.